Tencent and Medopad conducts AI medical trials in London

 

 

Tencent’s Artificial Intelligence program clinical trial in London, aims to diagnose patients with Parkinson’s disease, in partnership with a British start-up Medopad, who are planning to target not only Parkinson’s but also multiple sclerosis and psoriasis. Fan Wei head of Tencent’s Medical AI Lab said “We find our path is coming closer and closer”.

The Parkinson’s clinical trial will take place at Dementech Neurosciences, a private medical health clinic in London involving 40 patients and will take next few months.

Medopad, like DeepMind has partnerships with several British hospitals including the Royal Free and Royal Wolverhampton, which use its technology to remotely monitor patients.

The start-up had developed a smartphone app that enables doctors to gather information about patients by setting tests they can complete on their phones and collecting data from wearables and also developed diagnoses to doctors or alert them when patients

The Chinese tech company was asked two years ago by the Chinese governments to lead efforts to develop AI programs for medical diagnosis.

Medopad valued at $100m, was founded in 2011 by MR Vahdat, a bioengineering graduate who dropped out of a PhD at Johns Hopkins University to become an entrepreneur.